Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | CPT2 | P23786 | 1/20 | 0.39 |
| ▸ | CPT1A | P50416 | 1/20 | 0.39 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.38 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20912880 | 0.88 | HDAC3 (0.39) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL10859988 | 0.88 | CPT2 (0.43) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL10861574 | 0.81 | NPSR1 (0.47) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL19737233 | 0.81 | NPSR1 (0.48) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL10860219 | 0.80 | NPSR1 (0.46) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL10896745 | 0.79 | CCNE2 (0.39) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL11713511 | 0.78 | TSHR (0.50) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL11713886 | 0.78 | TSHR (0.50) | HPGDL3MBTL1NPSR1MAPK1TSHR | |
| SCHEMBL19737232 | 0.77 | CPT2 (0.32) | CPT2CPT1ACPT1B | |
| SCHEMBL10862500 | 0.76 | HPGD (0.43) | HPGDL3MBTL1NPSR1MAPK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2020-05-19 | — | — | US | disclosed |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2019-08-01 | — | — | US | disclosed |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Harbin Zhenbao Pharmaceutical Co., Ltd. (CN) | 2019-08-01 | — | — | US | disclosed |
| EP-3473628-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | Medshine Discovery Inc. (CN) | 2019-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10654868-B2 | Dihydropyrazole azepine compound serving as Akt inhibitor | AKT3, AKT2, AKT1 | HPGD 2975/4885L3MBTL1 4602/4885NPSR1 4516/4885 |
| US-20190233434-A1 | DIHYDROPYRAZOLE AZEPINE COMPOUND SERVING AS AKT INHIBITOR | AKT3, AKT2, AKT1 | HPGD 2975/4885L3MBTL1 4602/4885NPSR1 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.